This site is intended for healthcare professionals
Search

Find disease awareness content and relevant supporting materials

Drug information
11/12/17

Cefotaxime 500mg powder for solution for injection vials

Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cefotaxime sodium is indicated for the treatment of the following severe infections when known or thought very likely to be due to organisms that are susceptible to cefotaxime. ▪ Infections of the lower respiratory tract ▪ Infections of the kidneys and urinary tract ▪ Infections of the skin and soft tissue ▪ Genital infections caused by gonococci, particularly when penicillin has failed or is unsuitable ▪ Intra-abdominal infections (including Peritonitis) ▪ Lyme-borreliosis (especially stages II and III) ▪ Acute Meningitis in case of gram-negative microorganisms in combination with another suitable antibiotic ▪ Sepsis in case of gram-negative microorganism in combination with another suitable antibiotic ▪ Endocarditis in case of gram-negative microorganism in combination with another suitable antibiotic Peri-operative prophylaxis in surgical procedures such as colorectal, gastrointestinal, prostatic, urogenital and gynaecological surgery in patients who have a definite risk of post-operative infections. Cefotaxime should be used in combination with another antibiotic that can provide anaerobic cover in the treatment of intra-abdominal infections. Cefotaxime should be used in combination with an aminoglycoside in the treatment of infections caused by Pseudomonas. Protection is best insured by achieving adequate local tissue concentrations at the time contamination is likely to occur. Administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infection.

Drug information
11/12/17

Cefotaxime 1g powder for solution for injection vials

Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cefotaxime sodium is indicated for the treatment of the following severe infections when known or thought very likely to be due to organisms that are susceptible to cefotaxime. ▪ Infections of the lower respiratory tract ▪ Infections of the kidneys and urinary tract ▪ Infections of the skin and soft tissue ▪ Genital infections caused by gonococci, particularly when penicillin has failed or is unsuitable ▪ Intra-abdominal infections (including Peritonitis) ▪ Lyme-borreliosis (especially stages II and III) ▪ Acute Meningitis in case of gram-negative microorganisms in combination with another suitable antibiotic ▪ Sepsis in case of gram-negative microorganism in combination with another suitable antibiotic ▪ Endocarditis in case of gram-negative microorganism in combination with another suitable antibiotic Peri-operative prophylaxis in surgical procedures such as colorectal, gastrointestinal, prostatic, urogenital and gynaecological surgery in patients who have a definite risk of post-operative infections. Cefotaxime should be used in combination with another antibiotic that can provide anaerobic cover in the treatment of intra-abdominal infections. Cefotaxime should be used in combination with an aminoglycoside in the treatment of infections caused by Pseudomonas. Protection is best insured by achieving adequate local tissue concentrations at the time contamination is likely to occur. Administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infection.